|
TSO - Additional Information (Detail)
|
1 Months Ended | 3 Months Ended | 9 Months Ended | 87 Months Ended | 1 Months Ended | 3 Months Ended | 9 Months Ended | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Feb. 22, 2013
|
Sep. 30, 2013
USD ($)
|
Sep. 30, 2012
USD ($)
|
Sep. 30, 2013
USD ($)
|
Sep. 30, 2012
USD ($)
|
Sep. 30, 2013
USD ($)
|
Feb. 22, 2013
Research and Development Arrangement [Member]
|
Feb. 22, 2013
Joint Ownership and Exclusive License Agreement Fu Berlin [Member]
USD ($)
|
Feb. 22, 2013
Joint Ownership and Exclusive License Agreement Fu Berlin [Member]
EUR (€)
|
Feb. 22, 2013
Joint Ownership and Exclusive License Agreement Fu Berlin [Member]
Minimum [Member]
|
Feb. 22, 2013
Joint Ownership and Exclusive License Agreement Fu Berlin [Member]
Maximum [Member]
|
Sep. 30, 2013
Joint Ownership and Exclusive License Agreement Fu Berlin [Member]
Research and Development Arrangement [Member]
USD ($)
|
Sep. 30, 2013
Joint Ownership and Exclusive License Agreement Fu Berlin [Member]
Research and Development Arrangement [Member]
USD ($)
|
Feb. 22, 2013
Joint Ownership and Exclusive License Agreement Fu Berlin [Member]
Research and Development Arrangement [Member]
USD ($)
|
Feb. 22, 2013
Joint Ownership and Exclusive License Agreement Fu Berlin [Member]
Research and Development Arrangement [Member]
EUR (€)
|
Feb. 22, 2013
License and Sublicense Agreement with Ovamed GmbH [Member]
Minimum [Member]
|
Feb. 22, 2013
License and Sublicense Agreement with Ovamed GmbH [Member]
Maximum [Member]
|
Feb. 22, 2013
Maximum Potential Consideration Receivable upon Achievement of Milestone [Member]
USD ($)
|
Feb. 22, 2013
Maximum Potential Consideration Receivable upon Achievement of Milestone [Member]
EUR (€)
|
|
| Long-term Purchase Commitment [Line Items] | |||||||||||||||||||
| Expected project duration under research agreement | 4 years | ||||||||||||||||||
| Research fees to be paid under agreement | $ 853,000 | € 648,000 | |||||||||||||||||
| Written notice period under research agreement termination | 3 months | ||||||||||||||||||
| Research and development expense | 5,361,000 | 3,777,000 | 19,130,000 | 12,893,000 | 61,139,000 | 52,500 | 127,400 | ||||||||||||
| Potential milestone payments based primarily on the achievement of clinical development and regulatory milestones | 4,982,000 | 3,830,000 | |||||||||||||||||
| Percentage of royalty on net sales of products range | 1.00% | 2.50% | 1.00% | 2.50% | |||||||||||||||
| Notice period to cure termination due to breach | 60 days | ||||||||||||||||||
| Period of notice for termination of Joint Ownership and exclusive license agreement | 60 days | ||||||||||||||||||
| Period of Written notice for termination of Joint Ownership and exclusive license agreement | 180 days | ||||||||||||||||||
| Maximum potential payment based on achievement of regulatory milestones | $ 1,333,000 | € 1,025,000 | |||||||||||||||||
| Right Interest in Joint Intellectual Property | 10.00% | ||||||||||||||||||